These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 15959614

  • 1. A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.
    Reginster JY, Felsenberg D, Cooper C, Stakkestad JA, Miller PD, Kendler DL, Adami S, McClung MR, Bolognese MA, Civitelli R, Dumont E, Bonvoisin B, Recker RR, Delmas PD.
    Osteoporos Int; 2006 Feb; 17(2):159-66. PubMed ID: 15959614
    [Abstract] [Full Text] [Related]

  • 2. Once-monthly dosing: an effective step forward.
    Reid DM.
    Bone; 2006 Apr; 38(4 Suppl 1):S18-22. PubMed ID: 16533625
    [Abstract] [Full Text] [Related]

  • 3. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
    Pyon EY.
    Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
    [Abstract] [Full Text] [Related]

  • 4. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
    Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, Reginster JY, Recker RR, Hughes C, Lewiecki EM, Felsenberg D, Delmas PD, Kendler DL, Bolognese MA, Mairon N, Cooper C.
    J Bone Miner Res; 2005 Aug; 20(8):1315-22. PubMed ID: 16007327
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review.
    Reginster JY.
    Curr Pharm Des; 2005 Aug; 11(28):3711-28. PubMed ID: 16305506
    [Abstract] [Full Text] [Related]

  • 7. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
    Rossini M, Viapiana O, Gatti D, Adami S.
    Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
    [Abstract] [Full Text] [Related]

  • 8. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
    Chesnut CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD, Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE).
    J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials.
    Lee YH, Song GG.
    Korean J Intern Med; 2011 Sep; 26(3):340-7. PubMed ID: 22016595
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [Abstract] [Full Text] [Related]

  • 16. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies.
    Schimmer RC, Bauss F.
    Clin Ther; 2003 Jan; 25(1):19-34. PubMed ID: 12637110
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
    Miller PD.
    Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
    [Abstract] [Full Text] [Related]

  • 19. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study.
    Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauskaite D, Ward P, Sambrook P, Reid DM.
    Arthritis Rheum; 2006 Jun; 54(6):1838-46. PubMed ID: 16729277
    [Abstract] [Full Text] [Related]

  • 20. Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis.
    Reginster JY.
    Expert Opin Pharmacother; 2005 Oct; 6(13):2301-13. PubMed ID: 16218890
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.